Home  /  Resource Library  /  Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After > 2 Lines of Therapy: Matching-Adjusted Indirect Comparison

Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After > 2 Lines of Therapy: Matching-Adjusted Indirect Comparison

Match adjusted study comparing Loncastuximab tesirine with polatuzumab vedotin for treatment of relapsed DLBCL.